Although transition to dexamethasone plus an IL-6 or JAK inhibitor is warranted, this does not prevent the occurrence of DDIs due to ongoing CYP inhibition.23 If the admission is unrelated to COVID-19, completion of the ritonavir-boosted nirmatrelvir course would be reasonable. This evidence concerns the gene IL6 and COVID-19.